Comparison of safety of lecanemab and aducanumab: a real-world disproportionality analysis using the FDA adverse event reporting system
Four signal calculation methods were used to assess potential adverse reaction signals of lecanemab and aducanumab. This study identified some new PT signals and some PT signals showed gender differences. The median time-to-onset of ADEs due to lecanemab is shorter than that due to aducanumab.
Authors
- Lingti Kong (ORCID: https://orcid.org/0000-0003-0769-9363)
- Xiaohu Yang (ORCID: https://orcid.org/0000-0002-5871-7894)
- Jianming Xu (ORCID: https://orcid.org/0000-0003-4467-6021)
Institutions
- Bengbu Medical College (CN)
- First Affiliated Hospital of Bengbu Medical College (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-05-30
- DOI
- https://doi.org/10.3389/fphar.2025.1593989
- Citations
- 4
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 12.52